MedTrace Logo

Intravitreal Faricimab in Patients With Refractory Macular Edema

NCT07093385 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2025-07-30

No results posted yet for this study

Summary

This prospective study will include about 40 patients with resistant wet age-related macular degeneration (AMD), diabetic macular edema (DME), or retinal vein occlusion edema (RVO) edema.The inclusion criteria are that all patients must be 40 years old or older, diagnosed with active wet AMD or macular edema due to RVO or DME, and have received at least four previous monthly injections of anti-VEGF other than faricimab. All patients will be switched to receive four loading doses of intravitreal faricimab (6 mg) at 4-week intervals for four months. The response to faricimab will be assessed regarding visual acuity and central macular thickness.

Conditions

  • Age-Related Macular Degeneration

Interventions

DRUG

Faricimab Injection

Faricimab (6 mg/0.05 mL) for three months (loading dose) in a sterile environment,

Sponsors & Collaborators

  • Baghdad college of medicine

    lead OTHER

Principal Investigators

  • Duaa J Kadhim · Baghdad college of medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
45 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-10
Primary Completion
2025-06-01
Completion
2025-07-01
FDA Drug
Yes

Countries

  • Iraq

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07093385 on ClinicalTrials.gov